Near Dresden, in the former GDR, the German start-up Demecan has been producing therapeutic cannabis since 2021, the sale of which has been authorized in the Federal Republic since 2017. Production, strictly regulated by narcotics legislation, is currently exclusively intended for the medical market.
But another – colossal – market could emerge: the new majority in power in Berlin has announced in its coalition program the forthcoming liberalization of recreational cannabis for a test period of four years, after which an initial assessment will be drawn up. No date has yet been set. The needs are estimated at between 300 and 400 tons per year, or 1.2 to 1.5 billion euros in turnover, much more than the needs for therapeutic cannabis. Investors are already in the starting blocks to capture this colossal market.